This is a mobile optimized page that loads fast, if you want to load the real page, click this text.

ALA - Arovella Therapeutics

Jump to new
Dropped back quickly from the 15c at the end of last month but seems to be starting to pick up the last few days. Not much in the quarterly, just building towards a phase 1 trial for non Hodgin's Lymphoma, so likely to be slow progress for the rest of the year.
 
Another one of my picks that is going backwards on no news. Likely to be slow for a while as little news likely for a while.
 
Has had a pretty good month after announcing the manufacturing scale up of ALA 101, allowing it to produce sufficient quantities for the phase 1 clinical trials.
 
Another champion line past financial year. just give a bit 3 more cents tickle and she will challenge her all time high.
 
Almost got tickled. My MTF trend following system. Another happy day indeed

Again I need to put a disclaimer here not a recommendation to buy and sell

 
Quarterly out last week outlining program for next year leading to first in human clinical trials and pointing to healthy cash balance after the raising earlier this year. Looks like fairly slow progress as with all biotechs, however a very promising technology.
 
Not much new in the annual report, still waiting for progress to human trials. Slowly drifting back down. Still had 12 million cash at the end of the financial year which should last them till the trials start.
 
Pocketed a 3 million dollar research grant which according to the quarterly will give them enough money to get results from the first human trials. Price holding pretty well.
 
You must log in or register to reply here.

Similar threads

SAS - Sky and Space Company
2 3
Replies
53
Views
16K
greggles
AB1 - Animoca Brands Corporation
Replies
15
Views
7K
she'll be right
S
G79 - Goldoz Limited
Replies
7
Views
6K
System
BIG - Big Un Limited
2 3
Replies
51
Views
19K
noirua
TKF - TikForce Limited
Replies
0
Views
4K
System
Menu
Log in
Register
Cookies are required to use this site. You must accept them to continue using the site. Learn more...